CN1604773A - 用1r,2s－甲氧胺治疗大便失禁和其他相关疾病 - Google Patents

用1r,2s－甲氧胺治疗大便失禁和其他相关疾病 Download PDF

Info

Publication number
CN1604773A
CN1604773A CNA028253248A CN02825324A CN1604773A CN 1604773 A CN1604773 A CN 1604773A CN A028253248 A CNA028253248 A CN A028253248A CN 02825324 A CN02825324 A CN 02825324A CN 1604773 A CN1604773 A CN 1604773A
Authority
CN
China
Prior art keywords
methoxamine
salt
tolerate
physiology
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028253248A
Other languages
English (en)
Chinese (zh)
Inventor
诺曼·巴雷斯
杰弗里·马丁·汤普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Norgine Europe BV
Original Assignee
Norgine Europe BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norgine Europe BV filed Critical Norgine Europe BV
Publication of CN1604773A publication Critical patent/CN1604773A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/70—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA028253248A 2001-12-21 2002-12-20 用1r,2s－甲氧胺治疗大便失禁和其他相关疾病 Pending CN1604773A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0130763.6 2001-12-21
GBGB0130763.6A GB0130763D0 (en) 2001-12-21 2001-12-21 Treatment methods

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNA2009101594203A Division CN101601665A (zh) 2001-12-21 2002-12-20 1r,2s-甲氧胺在制备治疗大便失禁和其他相关疾病的药物中的应用
CN2011104050612A Division CN102516101A (zh) 2001-12-21 2002-12-20 1r,2s-甲氧胺在制备治疗大便失禁和其他相关疾病的药物中的应用

Publications (1)

Publication Number Publication Date
CN1604773A true CN1604773A (zh) 2005-04-06

Family

ID=9928258

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2009101594203A Pending CN101601665A (zh) 2001-12-21 2002-12-20 1r,2s-甲氧胺在制备治疗大便失禁和其他相关疾病的药物中的应用
CNA028253248A Pending CN1604773A (zh) 2001-12-21 2002-12-20 用1r,2s－甲氧胺治疗大便失禁和其他相关疾病
CN2011104050612A Pending CN102516101A (zh) 2001-12-21 2002-12-20 1r,2s-甲氧胺在制备治疗大便失禁和其他相关疾病的药物中的应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA2009101594203A Pending CN101601665A (zh) 2001-12-21 2002-12-20 1r,2s-甲氧胺在制备治疗大便失禁和其他相关疾病的药物中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011104050612A Pending CN102516101A (zh) 2001-12-21 2002-12-20 1r,2s-甲氧胺在制备治疗大便失禁和其他相关疾病的药物中的应用

Country Status (12)

Country Link
US (3) US20050096397A1 (enExample)
EP (2) EP1458370A1 (enExample)
JP (3) JP5486143B2 (enExample)
CN (3) CN101601665A (enExample)
AU (1) AU2002353206B2 (enExample)
CA (1) CA2471046C (enExample)
GB (1) GB0130763D0 (enExample)
MX (1) MXPA04006142A (enExample)
PL (1) PL217404B1 (enExample)
RU (1) RU2332989C2 (enExample)
WO (1) WO2003055474A1 (enExample)
ZA (1) ZA200404813B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130763D0 (en) * 2001-12-21 2002-02-06 Norgine Res Ltd Treatment methods
GB0501580D0 (en) * 2005-01-25 2005-03-02 Norgine Europe Bv Compounds for treating urinary incontinence
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
ES2630102T3 (es) * 2011-04-26 2017-08-18 Rdd Pharma Ltd. Oximetazolina para el tratamiento de trastornos ano-rectales
CN102976961B (zh) * 2012-12-24 2014-09-24 武汉武药制药有限公司 盐酸甲氧明的制备方法
US10708086B2 (en) * 2016-01-19 2020-07-07 National Instruments Corporation Channel sounding techniques

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1593261A (en) * 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
JPS60172953A (ja) * 1984-02-17 1985-09-06 Sagami Chem Res Center 光学活性β−アミノアルコ−ルの製造方法
FR2647014B1 (fr) * 1989-05-16 1991-08-30 Paris V Universite Composition medicamenteuse pour le traitement et la prevention des symptomes de l'insuffisance cardiaque, renfermant un agent alpha-stimulant vasoconstricteur comme principe actif
DK339289D0 (da) 1989-07-07 1989-07-07 Dak Lab As Farmaceutisk praeparat
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
NL9102142A (nl) * 1991-12-20 1993-07-16 Dagra Pharma Bv Zetpillen met vertraagde afgifte en werkwijze voor de bereiding daarvan.
US6635678B1 (en) * 1996-12-23 2003-10-21 S.L.A. Pharma Ag Pharmaceutical composition for treating fecal incontinence
WO1998038587A1 (en) * 1997-02-26 1998-09-03 Siebel Systems, Inc. Method of using a cache to determine the visibility to a remote database client of a plurality of database transactions
US6539381B1 (en) * 1999-04-21 2003-03-25 Novell, Inc. System and method for synchronizing database information
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
US6544927B2 (en) * 2001-04-28 2003-04-08 University Of Florida Use of α2-adrenergic receptor agonists and adrenergic inhibitors in reducing defoliation
GB0130763D0 (en) 2001-12-21 2002-02-06 Norgine Res Ltd Treatment methods
US7089228B2 (en) * 2002-04-18 2006-08-08 International Business Machines Corporation Computer apparatus and method for caching results of a database query

Also Published As

Publication number Publication date
WO2003055474A1 (en) 2003-07-10
US20100022657A1 (en) 2010-01-28
GB0130763D0 (en) 2002-02-06
MXPA04006142A (es) 2005-03-31
PL369828A1 (en) 2005-05-02
US20050096397A1 (en) 2005-05-05
PL217404B1 (pl) 2014-07-31
JP2005519888A (ja) 2005-07-07
CA2471046A1 (en) 2003-07-10
US8613948B2 (en) 2013-12-24
JP5544535B2 (ja) 2014-07-09
JP2012025782A (ja) 2012-02-09
CN101601665A (zh) 2009-12-16
ZA200404813B (en) 2005-10-26
EP2275099A1 (en) 2011-01-19
JP2011105770A (ja) 2011-06-02
AU2002353206B2 (en) 2008-09-04
RU2332989C2 (ru) 2008-09-10
CA2471046C (en) 2012-02-07
RU2004122639A (ru) 2005-05-10
AU2002353206A1 (en) 2003-07-15
CN102516101A (zh) 2012-06-27
EP1458370A1 (en) 2004-09-22
US20130072567A1 (en) 2013-03-21
JP5486143B2 (ja) 2014-05-07
US8491931B2 (en) 2013-07-23

Similar Documents

Publication Publication Date Title
CN1153568C (zh) 在受体控制钙通道新部位显活性的治疗神经性疾病化合物
CN1088585C (zh) 在受体操纵性钙通道上的新位点具有活性的可用于治疗神经障碍和其他疾病的化合物
CN1096853C (zh) N－炔丙基－1－氨基二氢化茚的r－对映体、其盐和组合物的应用
CN1180844C (zh) 止痒药物
CN1216864C (zh) 烟碱性受体激动剂的正调节剂
CN1156451C (zh) β2-肾上腺受体激动剂
CN1156445C (zh) 采用二氢异吲哚衍生物抑制淀粉样蛋白聚集和使淀粉样蛋白沉积成像的方法
CN1690041A (zh) 3，3－二苯基丙胺衍生物
CN1402702A (zh) β2肾上腺素能受体激动剂
CN1133593A (zh) 用于治疗的哌嗪化合物
CN1237978A (zh) N－(芳基/杂芳基)氨基酸衍生物、包括这些衍生物的药用组合物以及用这些化合物抑制β－淀粉样肽释放和或其合成的方法
CN1113436A (zh) 药物反应的增效作用
CN1486690A (zh) 具有局部麻醉和抗炎活性的药用盐及其制备方法
CN1154496C (zh) 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用
CN1805938A (zh) 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
CN1450998A (zh) 含铜的胺氧化酶的抑制剂
CN1520290A (zh) 含铜胺氧化酶的碳环肼基抑制剂
CN1295479A (zh) β2－肾上腺素能受体激动剂
CN1864675A (zh) 柚皮素及其衍生物用于制备抗心脑系统疾病产品的用途
CN1750817A (zh) 米那普仑(1s,2r)对映体在药品制备方面的用途
CN1238771A (zh) 用作α－2肾上腺素能受体兴奋剂的2－咪唑啉基氨基吲哚化合物
CN1036064C (zh) 新的具有ngf生成促进活性的苯衍生物的制备方法
CN1878546A (zh) 治疗抑郁症和焦虑症的包括α－2δ配体和SSRI和/或SNRI的联用药物
CN1111986A (zh) 治疗肠应激综合症的异噁唑衍生物
CN1511137A (zh) 疏水性多胺类似物及其使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication